Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease

International Journal of COPD

Volumn 8, Issue , 2012, Pages 1-5

  Hataji, Osamu ^a   Naito, Masahiro ^a   Ito, Kentaro ^a   Watanabe, Fumiaki ^a   Gabazza, Esteban C ^b   Taguchi, Osamu ^c  

^a Matsusaka Municipal Hospital   (Japan)

^b Department of Immunology ^*  (Japan)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic obstructive pulmonary disease; Indacaterol; Long acting 2 agonist; Physical activity

Indexed keywords

INDACATEROL; TIOTROPIUM BROMIDE;

ACCELEROMETER; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DRUG EFFICACY; ENERGY EXPENDITURE; FEMALE; HUMAN; INHALER; LUNG FUNCTION; MALE; PHYSICAL ACTIVITY; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT OUTCOME;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; INDACATEROL; LONG-ACTING Β2-AGONIST; PHYSICAL ACTIVITY;

ACCELEROMETRY; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; MALE; MOTOR ACTIVITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 84872282237     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S38548     Document Type: Article

References (27)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, man-agement, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-555.
2. Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012;7:457-494.
3. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8:183-192.
4. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149.
5. Beier J, Beeh KM. Long-acting beta-adrenoceptor agonists in the man-agement of COPD: focus on indacaterol. Int J Chron Obstruct Pulmon Dis. 2011;6:237-243.
6. McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs. 2012;72:543-563.
7. Cope S, Zhang J, Williams J, Jansen JP. Efficacy of once-daily indacaterol 75 mug relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med. 2012;12:29.
8. Ribeiro M, Chapman KR. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2012;7:145-152.
9. Rossi A, Centanni S, Cerveri I, et al. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med. 2011;106:84-90.
10. Mroz RM, Minarowski L, Chyczewska E. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients. Adv Exp Med Biol. 2013;756:23-28.
11. O'Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105:1030-1036.
12. Casaburi R. Activity monitoring in assessing activities of daily living. COPD. 2007;4:251-255.
13. Cazzola M, Segreti A, Stirpe E, Appodia M, Senis L, Matera MG. Energy expenditure and impact of bronchodilators in COPD patients. Respir Med. 2010;104:1490-1494.
14. Lahaije AJ, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Physiologic limitations during daily life activities in COPD patients. Respir Med. 2010;104:1152-1159.
15. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:972-977.
16. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med. 2012;106:522-530.
17. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33:262-272.
18. Benzo RP, Chang CC, Farrell MH, et al. Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease. Respiration. 2010;80:10-18.
19. Garcia-Rio F, Rojo B, Casitas R, et al. Prognostic value of the objec-tive measurement of daily physical activity in COPD patients. Chest. 2012;142:338-346.
20. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest. 2006;129:536-544.
21. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140:331-342.
22. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med. 2012;106:522-530.
23. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-117.
24. Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med. 2012;185:1218-1224.
25. Kumahara H, Schutz Y, Ayabe M, et al. The use of uniaxial accelerom-etry for the assessment of physical-activity-related energy expenditure: a validation study against whole-body indirect calorimetry. Br J Nutr. 2004;91:235-243.
26. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473-479.
27. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10:11.